RSLV-132 Market Summary

Key Factors Driving RSLV-132 Growth

1. First-in-class mechanism targeting RNA-driven inflammation

• RSLV-132 is a novel RNase–Fc fusion biologic designed to degrade extracellular RNA, a key trigger of type I interferon–mediated inflammation in autoimmune diseases.

• It directly targets upstream disease biology (RNA-containing immune complexes activating TLR7/8), rather than downstream immunosuppression.

2. Clinical efficacy signals in Sjögren’s syndrome (fatigue improvement)

• Phase II randomized trial (≈30 patients):

o Demonstrated clinically meaningful improvements in fatigue endpoints (FACIT-F, ESSPRI, ProF, DSST) vs placebo.

• Fatigue is a major unmet need in Sjögren’s with limited approved therapies addressing it. 

3. Favorable pharmacokinetics and safety profile

• Phase I data in lupus:

o ~19-day half-life, supporting monthly dosing

o No anti-drug antibodies detected and good tolerability

Growth implication:

• Long half-life + low immunogenicity →

o Improved compliance

o Lower administration burden

o Competitive advantage vs frequent biologic dosing

4. Broad pipeline applicability across multiple indications

Clinical evaluation spans multiple RNA-driven conditions:

• Primary Sjögren’s syndrome (lead indication)

• Systemic lupus erythematosus (SLE)

• Post-acute COVID (PASC / long COVID fatigue)

• In SLE Phase IIa:

o Higher response rates in severe subgroup (e.g., SRI-4: 39% vs 8% placebo)

Growth implication:

• Platform potential → label expansion opportunities

• Risk diversification across autoimmune and inflammatory diseases

5. Signal of efficacy in high-disease-activity populations

• SLE study suggests better outcomes in patients with higher disease activity

Growth implication:

• Enables targeted patient stratification strategy, improving probability of success in future trials and commercialization.

6. Non-immunosuppressive therapeutic approach

• Mechanism removes pathogenic RNA without broadly suppressing immune cells.

Growth implication:

• Potential for:

o Lower infection risk vs traditional immunosuppressants

o Use in combination regimens

o Appeal in chronic autoimmune settings

 

RSLV-132 Recent Developments

• In May 2025, Resolve Therapeutics announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma. A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of these patients experience poor clinical outcomes due to Systemic Inflammatory Response Syndrome (SIRS). The mechanism of SIRS in polytrauma patients is not completely understood but the current view holds that that massive tissue injury results in the release of large amounts of RNA into the blood overwhelming the activity of circulating RNase, which protects cells from the inflammatory effects of cfRNA under normal circumstances. The accumulating cfRNA activates several key mechanisms driving local and systemic inflammation which leads to increased morbidity and mortality.

• In May 2024, Resolve Therapeutics announced the publication of its Phase II long COVID results in Clinical Infectious Diseases. The publication entitled ""Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A randomized Phase II trial of RSLV-132"" evaluated the impact of RNase in one hundred and eight patients diagnosed with COVID-19 at least 6 months prior to baseline and with a history of continuous, severe fatigue. Participants received 6 doses of RSLV-132 or placebo over two months. The study measured fatigue and overall disease activity using the PROMIS SF 10a, FACIT-Fatigue, and physician's global assessment.  

“RSLV-132 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of RSLV-132 for potential indication like Sjogren’s syndrome, Post acute COVID 19 syndrome, Subarachnoid haemorrhage, and Systemic lupus erythematosus in the 7MM. A detailed picture of RSLV-132’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the RSLV-132 for potential indications. The RSLV-132 market report provides insights about RSLV-132’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current RSLV-132 performance, future market assessments inclusive of the RSLV-132 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of RSLV-132 sales forecasts, along with factors driving its market.

 

RSLV-132 Drug Summary

RSLV-132 is an investigational biologic therapy developed for the treatment of autoimmune diseases, particularly Sjogren's Syndrome and Systemic Lupus Erythematosus. It is a first-in-class RNase–Fc fusion protein that combines a human ribonuclease enzyme with the Fc portion of an antibody, enabling prolonged circulation time and enhanced stability. The drug is designed to selectively degrade extracellular RNA, which plays a key role in activating innate immune pathways and driving chronic inflammation in autoimmune conditions. By reducing RNA-mediated immune activation, RSLV-132 aims to lower interferon signaling and downstream inflammatory responses implicated in disease pathogenesis. Administered intravenously, it has demonstrated promising immunomodulatory effects and improvements in fatigue and disease activity in early-phase clinical studies, supporting its potential as a novel targeted therapy for RNA-driven autoimmune disorders. The report provides RSLV-132’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the RSLV-132 Market Report

The report provides insights into:

• A comprehensive product overview including the RSLV-132 MoA, description, dosage and administration, research and development activities in potential indication like Sjogren’s syndrome, Post acute COVID 19 syndrome, Subarachnoid haemorrhage, and Systemic lupus erythematosus.

• Elaborated details on RSLV-132 regulatory milestones and other development activities have been provided in RSLV-132 market report.

• The report also highlights RSLV-132‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The RSLV-132 market report also covers the patents information, generic entry and impact on cost cut.

• The RSLV-132 market report contains current and forecasted RSLV-132 sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The RSLV-132 market report also features the SWOT analysis with analyst views for RSLV-132 in potential indications.

 

Methodology

The RSLV-132 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

RSLV-132 Analytical Perspective by DelveInsight

• In-depth RSLV-132 Market Assessment

This RSLV-132 sales market forecast report provides a detailed market assessment of RSLV-132 for potential indication like Sjogren’s syndrome, Post acute COVID 19 syndrome, Subarachnoid haemorrhage, and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted RSLV-132 sales data uptil 2034.

• RSLV-132 Clinical Assessment

The RSLV-132 market report provides the clinical trials information of RSLV-132 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

RSLV-132 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

RSLV-132 Market Potential & Revenue Forecast

• Projected market size for the RSLV-132 and its key indications

• Estimated RSLV-132 sales potential (RSLV-132 peak sales forecasts)

• RSLV-132 Pricing strategies and reimbursement landscape

RSLV-132 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• RSLV-132 Market positioning compared to existing treatments

• RSLV-132 Strengths & weaknesses relative to competitors

RSLV-132 Regulatory & Commercial Milestones

• RSLV-132 Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

RSLV-132 Clinical Differentiation

• RSLV-132 Efficacy & safety advantages over existing drugs

• RSLV-132 Unique selling points

 

RSLV-132 Market Report Highlights

• In the coming years, the RSLV-132 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The RSLV-132 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RSLV-132’s dominance.

• Other emerging products for Sjogren’s syndrome, Post acute COVID 19 syndrome, Subarachnoid haemorrhage, and Systemic lupus erythematosus are expected to give tough market competition to RSLV-132 and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RSLV-132 in potential indications.

• Analyse RSLV-132 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted RSLV-132 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of RSLV-132 in potential indications.

 

Key Questions

• What is the class of therapy, route of administration and mechanism of action of RSLV-132? How strong is RSLV-132’s clinical and commercial performance?

• What is RSLV-132’s clinical trial status in each individual indications such as Sjogren’s syndrome, Post acute COVID 19 syndrome, Subarachnoid haemorrhage, and Systemic lupus erythematosus and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RSLV-132 Manufacturers?

• What are the key designations that have been granted to RSLV-132 for potential indications? How are they going to impact RSLV-132’s penetration in various geographies?

• What is the current and forecasted RSLV-132 market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of RSLV-132 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 

• What are the other emerging products available and how are these giving competition to RSLV-132 for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is RSLV-132? What is the duration of therapy and what are the geographical variations in cost per patient?